Pikeville Medical Center v. Genentech, Inc.

CourtDistrict Court, N.D. California
DecidedJune 6, 2022
Docket4:22-cv-01318
StatusUnknown

This text of Pikeville Medical Center v. Genentech, Inc. (Pikeville Medical Center v. Genentech, Inc.) is published on Counsel Stack Legal Research, covering District Court, N.D. California primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pikeville Medical Center v. Genentech, Inc., (N.D. Cal. 2022).

Opinion

Wdot ING. BPO EI IN

UNITED STATES JUDICIAL PANEL F I L EK D on MULTIDISTRICT LITIGATION MAY 24 2022 Mark C. McCartt Cl : » Clerk U.S. DISTRICT COURT IN RE: GENENTECH, INC., HERCEPTIN (TRASTUZUMAB) MARKETING AND SALES PRACTICES LITIGATION MDL No. 2700

(SEE ATTACHED SCHEDULE)

CONDITIONAL TRANSFER ORDER (CTO —6)

On April 7, 2016, the Panel transferred 8 civil action(s) to the United States District Court for the Northern District of Oklahoma for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. See 178 F.Supp.3d 1374 (J.P.M.L. 2016). Since that time, 5 additional action(s) have been transferred to the Northern District of Oklahoma. With the consent of that court, all such actions have been assigned to the Honorable Terence C. Kern. It appears that the action(s) on this conditional transfer order involve questions of fact that are common to the actions previously transferred to the Northern District of Oklahoma and assigned to Judge Kern. Pursuant to Rule 7.1 of the Rules of Procedure of the United States Judicial Panel on Multidistrict Litigation, the action(s) on the attached schedule are transferred under 28 U.S.C. § 1407 to the Northern District of Oklahoma for the reasons stated in the order of April 7, 2016, and, with the consent of that court, assigned to the Honorable Terence C. Kern. This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the Northern District of Oklahoma. The transmittal of this order to said Clerk shall be stayed 7 days from the entry thereof. If any party files a notice of opposition with the Clerk of the Panel within this 7-day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is FOR THE PANEL: pending.et is time, the LZ stay is lifted. ee □ east Ge ee BU May 24, 2022 CLERK’S OFFICE tee, John W. Nichols Clerk of the Panel

Wdot INU OPN eee I

IN RE: GENENTECH, INC., HERCEPTIN (TRASTUZUMAB) MARKETING AND SALES PRACTICES LITIGATION MDL No. 2700

SCHEDULE CTO-6 — TAG-ALONG ACTIONS

DIST DIV. C.A.NO. CASE CAPTION

CALIFORNIA NORTHERN CAN 4 22-01318 Pikeville Medical Center v. Genentech, Inc.

United States District Court Northern District of Oklahoma □ _. nereby:cartify that the foregoing is a true Copy of the original-on file in this. court) fi □□□□□ YF Mark G-McCartt (Me i yl Le Vege bat peepuly ee

Free access — add to your briefcase to read the full text and ask questions with AI

Related

In re Genentech Herceptin (trastuzumab) Marketing & Sales Practices Litigation
178 F. Supp. 3d 1374 (Judicial Panel on Multidistrict Litigation, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
Pikeville Medical Center v. Genentech, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/pikeville-medical-center-v-genentech-inc-cand-2022.